OVs with STING agonist, cytokines, and TME-modifying enzymes + hormone therapy (e.g. Tamoxifen + Aromatase inhibitors) for ER+/HER2- subtype of breast cancer; Bacillus Calmette-Guerin (BCG) or chemotherapy for bladder cancer + Checkpoint inhibitors. Here, CYP19A1 is linked to breast carcinoma.